CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: paricalcitol
Accession: CHEBI:7931
browse the term
Definition: A seco-cholestane that has formula C27H44O3.
Synonyms: exact_synonym: (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
related_synonym: 19-Nor-1alpha,25-dihydroxyvitamin D2; Formula=C27H44O3; InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1; InChIKey=BPKAHTKRCLCHEA-UBFJEZKGSA-N; SMILES=[H][C@@]1(CC[C@]2([H])[C@]1(C)CCC\\C2=C/C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\\C=C\\[C@H](C)C(C)(C)O; Zemplar
xref: CAS:131918-61-1; DrugBank:DB00910; Drug_Central:2066; KEGG:C08127; KEGG:D00930
xref_mesh: MESH:C084656
xref: Patent:EP387077; Patent:US5587497; Wikipedia:Paricalcitol
G
Aadac
arylacetamide deacetylase
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of AADAC mRNA
CTD
PMID:17715259
NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734
G
Adipoq
adiponectin, C1Q and collagen domain containing
increases expression
ISO
paricalcitol results in increased expression of ADIPOQ protein
CTD
PMID:25037058
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
G
Adipor1
adiponectin receptor 1
increases expression
ISO
paricalcitol results in increased expression of ADIPOR1 protein
CTD
PMID:25037058
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
G
Alpl
alkaline phosphatase, biomineralization associated
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of ALPL mRNA
CTD
PMID:17715259
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
G
Apoe
apolipoprotein E
multiple interactions
ISO
paricalcitol inhibits the reaction [APOE gene mutant form results in decreased abundance of Antioxidants]; paricalcitol inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol] [Phosphorus co-treated with paricalcitol] results in decreased expression of APOE mRNA
CTD
PMID:17715259 PMID:25037058
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
G
B4galt1
beta-1,4-galactosyltransferase 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of B4GALT1 mRNA
CTD
PMID:17715259
NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461
G
Bcl2
BCL2, apoptosis regulator
multiple interactions
ISO
[paricalcitol co-treated with arsenic trioxide] results in decreased expression of BCL2
CTD
PMID:15781666
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bcl2l1
Bcl2-like 1
multiple interactions
ISO
[paricalcitol co-treated with arsenic trioxide] results in decreased expression of BCL2L1
CTD
PMID:15781666
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
G
Bmp4
bone morphogenetic protein 4
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of BMP4 mRNA
CTD
PMID:17715259
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
G
Camp
cathelicidin antimicrobial peptide
multiple interactions
ISO
paricalcitol promotes the reaction [pterostilbene results in increased expression of CAMP mRNA]; paricalcitol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]
CTD
PMID:24039193
NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543
G
Ccl2
C-C motif chemokine ligand 2
multiple interactions decreases expression increases expression
ISO EXP
[paricalcitol co-treated with Enalapril] results in decreased expression of CCL2 protein paricalcitol results in decreased expression of CCL2 protein paricalcitol results in increased expression of CCL2 mRNA
CTD
PMID:17513326 PMID:20720404 PMID:25037058
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
G
Ccr2
C-C motif chemokine receptor 2
increases expression
ISO
paricalcitol results in increased expression of CCR2 mRNA
CTD
PMID:25037058
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
G
Cd14
CD14 molecule
increases expression multiple interactions
ISO
paricalcitol results in increased expression of CD14 protein [Phosphorus co-treated with paricalcitol] results in increased expression of CD14 mRNA
CTD
PMID:12618899 PMID:17715259
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
G
Ces1d
carboxylesterase 1D
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of CES1 mRNA
CTD
PMID:17715259
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
G
Col15a1
collagen type XV alpha 1 chain
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of COL15A1 mRNA
CTD
PMID:17715259
NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
G
Col1a1
collagen type I alpha 1 chain
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of COL1A1 mRNA
CTD
PMID:17715259
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
G
Col3a1
collagen type III alpha 1 chain
increases expression
ISO
paricalcitol results in increased expression of COL3A1 mRNA
CTD
PMID:25037058
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
G
Cp
ceruloplasmin
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of CP mRNA
CTD
PMID:17715259
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
G
Cpn2
carboxypeptidase N subunit 2
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of CPN2 mRNA
CTD
PMID:17715259
NCBI chr11:70,486,054...70,495,937
Ensembl chr11:70,486,057...70,496,472
G
Cpt1a
carnitine palmitoyltransferase 1A
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of CPT1A mRNA
CTD
PMID:17715259
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
G
Crip1
cysteine rich protein 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of CRIP1 mRNA
CTD
PMID:17715259
NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:132,226,746...132,234,620
G
Ctdspl
CTD small phosphatase like
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of CTDSPL mRNA
CTD
PMID:17715259
NCBI chr 8:118,642,729...118,767,238
Ensembl chr 8:118,642,672...118,767,117
G
Cyba
cytochrome b-245 alpha chain
multiple interactions decreases expression
ISO
[paricalcitol co-treated with Enalapril] results in decreased expression of CYBA protein paricalcitol results in decreased expression of CYBA protein
CTD
PMID:20720404
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
G
Cyp1b1
cytochrome P450, family 1, subfamily b, polypeptide 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of CYP1B1 mRNA
CTD
PMID:17715259
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
G
Cyp24a1
cytochrome P450, family 24, subfamily a, polypeptide 1
multiple interactions
ISO
[arsenic trioxide results in decreased expression of CYP24A1] which results in increased activity of paricalcitol; [Phosphorus co-treated with paricalcitol] results in increased expression of CYP24A1 mRNA
CTD
PMID:15781666 PMID:17715259
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of CYP2B6 mRNA
CTD
PMID:17715259
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp3a2
cytochrome P450, family 3, subfamily a, polypeptide 2
increases expression
ISO
paricalcitol results in increased expression of CYP3A4 mRNA
CTD
PMID:11723248
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
G
Edn1
endothelin 1
multiple interactions
EXP
paricalcitol inhibits the reaction [EDN1 protein results in increased expression of NPPA mRNA]; paricalcitol inhibits the reaction [EDN1 protein results in increased expression of PRKCA protein modified form]
CTD
PMID:21565836
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
G
Ednrb
endothelin receptor type B
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of EDNRB mRNA
CTD
PMID:17715259
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
G
Eng
endoglin
multiple interactions
ISO
[Enalapril co-treated with paricalcitol] results in decreased expression of ENG mRNA
CTD
PMID:25037058
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
G
Fbln2
fibulin 2
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of FBLN2 mRNA
CTD
PMID:17715259
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
G
Icam1
intercellular adhesion molecule 1
multiple interactions
ISO
[Enalapril co-treated with paricalcitol] results in decreased expression of ICAM1 mRNA
CTD
PMID:25037058
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
G
Id3
inhibitor of DNA binding 3
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of ID3 mRNA
CTD
PMID:17715259
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
G
Il11
interleukin 11
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of IL11 mRNA
CTD
PMID:17715259
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
G
Il1a
interleukin 1 alpha
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of IL1A mRNA
CTD
PMID:17715259
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
G
Il1b
interleukin 1 beta
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of IL1B mRNA
CTD
PMID:17715259
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
G
Il1rn
interleukin 1 receptor antagonist
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of IL1RN mRNA
CTD
PMID:17715259
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
G
Il24
interleukin 24
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of IL24 mRNA
CTD
PMID:17715259
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
G
Il36rn
interleukin 36 receptor antagonist
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of IL36RN mRNA
CTD
PMID:17715259
NCBI chr 3:7,044,419...7,051,016
Ensembl chr 3:7,044,406...7,051,016
G
Il6
interleukin 6
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of IL6 mRNA
CTD
PMID:17715259
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
G
Itga2
integrin subunit alpha 2
decreases expression
ISO
paricalcitol results in decreased expression of ITGA2 mRNA
CTD
PMID:25037058
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
G
Itgam
integrin subunit alpha M
increases expression
ISO
paricalcitol results in increased expression of ITGAM protein
CTD
PMID:12618899
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
G
Mapk13
mitogen activated protein kinase 13
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of MAPK13 mRNA
CTD
PMID:17715259
NCBI chr20:6,835,277...6,845,500
Ensembl chr20:6,835,320...6,844,222
G
Meltf
melanotransferrin
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of MELTF mRNA
CTD
PMID:17715259
NCBI chr11:68,884,446...68,906,300
Ensembl chr11:68,884,446...68,906,300
G
Mgp
matrix Gla protein
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of MGP mRNA
CTD
PMID:17715259
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
G
Mrpl33
mitochondrial ribosomal protein L33
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of MRPL33 mRNA
CTD
PMID:17715259
NCBI chr 6:24,825,800...24,833,994
Ensembl chr 6:24,825,827...24,833,834
G
Ncor1
nuclear receptor co-repressor 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the localization of NCOR1 protein; [Phosphorus co-treated with paricalcitol] results in decreased expression of NCOR1 protein
CTD
PMID:17715259
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
G
Nos2
nitric oxide synthase 2
multiple interactions decreases expression
ISO
[paricalcitol co-treated with Enalapril] results in decreased expression of NOS2 protein paricalcitol results in decreased expression of NOS2 protein
CTD
PMID:20720404
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
G
Nos3
nitric oxide synthase 3
multiple interactions increases expression
ISO
[paricalcitol co-treated with Enalapril] results in increased expression of NOS3 protein paricalcitol results in increased expression of NOS3 protein
CTD
PMID:20720404 PMID:25037058
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
G
Nppa
natriuretic peptide A
multiple interactions
EXP
paricalcitol inhibits the reaction [EDN1 protein results in increased expression of NPPA mRNA]; paricalcitol inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
CTD
PMID:21565836
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
G
Npy
neuropeptide Y
increases expression
ISO
paricalcitol results in increased expression of NPY mRNA
CTD
PMID:25037058
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
G
Nr4a1
nuclear receptor subfamily 4, group A, member 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of NR4A1 mRNA
CTD
PMID:17715259
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
G
Nr4a2
nuclear receptor subfamily 4, group A, member 2
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of NR4A2 mRNA
CTD
PMID:17715259
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
G
Pex11a
peroxisomal biogenesis factor 11 alpha
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of PEX11A mRNA
CTD
PMID:17715259
NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172
G
Postn
periostin
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of POSTN mRNA
CTD
PMID:17715259
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
G
Pparg
peroxisome proliferator-activated receptor gamma
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased localization of PPARG protein
CTD
PMID:17715259
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
G
Prkaa1
protein kinase AMP-activated catalytic subunit alpha 1
increases expression
ISO
paricalcitol results in increased expression of PRKAA1 protein
CTD
PMID:25037058
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
G
Prkca
protein kinase C, alpha
multiple interactions decreases expression
EXP
paricalcitol inhibits the reaction [EDN1 protein results in increased expression of PRKCA protein modified form]; paricalcitol inhibits the reaction [Phenylephrine results in increased expression of PRKCA protein modified form] paricalcitol results in decreased expression of PRKCA protein modified form
CTD
PMID:21565836
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
G
Ptgs1
prostaglandin-endoperoxide synthase 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of PTGS1 mRNA
CTD
PMID:17715259
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions decreases expression
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of PTGS2 mRNA paricalcitol results in decreased expression of PTGS2 protein [paricalcitol co-treated with Enalapril] results in decreased expression of PTGS2 protein
CTD
PMID:17715259 PMID:20720404 PMID:25037058
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Pth
parathyroid hormone
decreases secretion decreases expression
ISO
paricalcitol results in decreased secretion of PTH protein paricalcitol results in decreased expression of PTH protein
CTD
PMID:12631365 PMID:15898824
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
G
Rarres1
retinoic acid receptor responder 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of RARRES1 mRNA
CTD
PMID:17715259
NCBI chr 2:151,749,715...151,783,975
Ensembl chr 2:151,749,715...151,783,978
G
Rela
RELA proto-oncogene, NF-kB subunit
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased localization of RELA protein
CTD
PMID:17715259
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Ren
renin
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in decreased expression of REN1 mRNA
CTD
PMID:17715259
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
G
Sell
selectin L
multiple interactions
ISO
[Enalapril co-treated with paricalcitol] results in decreased expression of SELL mRNA
CTD
PMID:25037058
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
G
Serpine1
serpin family E member 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of SERPINE1 mRNA; [Phosphorus co-treated with paricalcitol] results in decreased expression of SERPINE1 protein
CTD
PMID:17715259
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
G
Smad2
SMAD family member 2
decreases phosphorylation multiple interactions
EXP
paricalcitol results in decreased phosphorylation of SMAD2 protein Enalapril promotes the reaction [paricalcitol results in decreased phosphorylation of SMAD2 protein]
CTD
PMID:17513326
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
G
Sod1
superoxide dismutase 1
increases expression multiple interactions
ISO
paricalcitol results in increased expression of SOD1 protein [paricalcitol co-treated with Enalapril] results in increased expression of SOD1 protein
CTD
PMID:20720404 PMID:25037058
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
G
Sod2
superoxide dismutase 2
decreases expression multiple interactions
ISO
paricalcitol results in decreased expression of SOD2 protein [paricalcitol co-treated with Enalapril] results in decreased expression of SOD2 protein
CTD
PMID:20720404 PMID:25037058
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Sod3
superoxide dismutase 3
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of SOD3 mRNA
CTD
PMID:17715259
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
G
Spp1
secreted phosphoprotein 1
multiple interactions increases expression
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of SPP1 mRNA [Enalapril co-treated with paricalcitol] results in decreased expression of SPP1 mRNA paricalcitol results in increased expression of SPP1 mRNA
CTD
PMID:17715259 PMID:25037058
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Tgfb1
transforming growth factor, beta 1
multiple interactions decreases expression
EXP
Enalapril promotes the reaction [paricalcitol results in decreased expression of TGFB1 mRNA]; Enalapril promotes the reaction [paricalcitol results in decreased expression of TGFB1 protein] paricalcitol results in decreased expression of TGFB1 mRNA; paricalcitol results in decreased expression of TGFB1 protein
CTD
PMID:17513326
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
G
Tgfb3
transforming growth factor, beta 3
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of TGFB3 mRNA
CTD
PMID:17715259
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
G
Thbd
thrombomodulin
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of THBD mRNA; [Phosphorus co-treated with paricalcitol] results in increased expression of THBD protein
CTD
PMID:17715259
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
G
Thbs1
thrombospondin 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of THBS1 mRNA; [Phosphorus co-treated with paricalcitol] results in decreased expression of THBS1 protein
CTD
PMID:17715259
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
G
Tnf
tumor necrosis factor
decreases expression multiple interactions
ISO EXP
paricalcitol results in decreased expression of TNF protein [paricalcitol co-treated with Enalapril] results in decreased expression of TNF protein paricalcitol inhibits the reaction [Doxorubicin results in increased expression of TNF protein]
CTD
PMID:20720404 PMID:25037058 PMID:32812453
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
G
Tnfrsf11b
TNF receptor superfamily member 11B
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] affects the expression of TNFRSF11B mRNA; [Phosphorus co-treated with paricalcitol] results in decreased expression of TNFRSF11B protein
CTD
PMID:17715259
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
G
Tnfsf11
TNF superfamily member 11
increases expression
EXP
paricalcitol results in increased expression of TNFSF11 mRNA; paricalcitol results in increased expression of TNFSF11 protein
CTD
PMID:17352647
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
G
Tnxb
tenascin XB
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of TNXB mRNA
CTD
PMID:17715259
G
Trem1
triggering receptor expressed on myeloid cells 1
multiple interactions
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of TREM1 mRNA
CTD
PMID:17715259
NCBI chr 9:12,763,819...12,779,285
Ensembl chr 9:12,763,819...12,779,203
G
Vdr
vitamin D receptor
multiple interactions affects binding
ISO
[Phosphorus co-treated with paricalcitol] results in increased expression of VDR protein; [Phosphorus co-treated with paricalcitol] results in increased localization of VDR protein; paricalcitol binds to and affects the activity of VDR protein paricalcitol binds to VDR protein
CTD
PMID:15898824 PMID:16076355 PMID:17715259
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
G
Vwf
von Willebrand factor
decreases expression
ISO
paricalcitol results in decreased expression of VWF mRNA
CTD
PMID:25037058
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all